HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
Rhea-AI Summary
HCW Biologics (NASDAQ: HCWB) closed an exclusive worldwide license with Beijing Trimmune Biotech for HCW11-006, receiving a $7.0 million upfront package (a $3.5 million cash payment plus $3.5 million in transferable equity) on March 17, 2026.
Trimmune will fund a Phase 1 China study expected in H1 2027; HCW retains a payment-free option to recapture Americas rights after Phase 1. HCW is eligible for development milestones, double-digit royalties, and proceeds from future transactions.
Positive
- Upfront package of $7.0 million received
- $3.5M cash payment completed on closing
- $3.5M minority transferable equity position in Trimmune
- Phase 1 in China funded by licensee, expected H1 2027
- Opt-in to recapture Americas rights after Phase 1
- Potential revenue from double-digit royalties and milestones
Negative
- HCW must rely on Trimmune to complete Phase 1 in China
- Americas development paused until HCW exercises opt-in after Phase 1
News Market Reaction – HCWB
In the Mar 17 session, HCWB declined 6.33%, reflecting a notable negative market reaction. Argus tracked a peak move of +29.6% during that session. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Preclinical research data | Positive | +60.9% | Publication showing HCW9206-generated CAR-T cells with improved persistence and activity. |
| Mar 02 | Nasdaq compliance regained | Positive | +1.7% | Nasdaq Panel confirmed full compliance, preserving access to public capital markets. |
| Feb 17 | Follow-on offering | Negative | -1.5% | At-the-market follow-on of $1.5M in units and repricing of existing warrants. |
| Feb 13 | JV Trimmune financing | Positive | -21.2% | Formation and funding of Trimmune JV to develop HCW11-006 with $7M package. |
| Nov 19 | Warrant inducement | Negative | -17.0% | Reduced warrant exercise prices to spur exercises, raising $4.0M and issuing new warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent HCWB news has often produced sharp reactions, with positive scientific or business updates frequently aligning with substantial price moves, while financing actions have generally pressured the stock.
Over the past few months, HCWB combined scientific, listing, and financing milestones. Positive CAR-T research results on Mar 16, 2026 drove a 60.92% gain, and regaining Nasdaq compliance on Mar 2, 2026 saw a modest uptick. By contrast, follow-on and warrant-related financings in Feb 2026 and Nov 2025 coincided with single- to double-digit declines. The February Trimmune joint venture announcement around HCW11-006 led to a steep selloff, making today’s completed-payment license news a reversal of that prior negative price response.
Key Terms
phase 1 clinical study medical
in vivo medical
royalties financial
transferable equity interest financial
clinical stage medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Upfront cash fee with total value of
Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027
HCW Biologics has “free” option to reclaim the rights to the Americas territory
MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced the receipt of full payment of the upfront license fee with a value of
Trimmune is a new operating entity responsible for the development and commercialization of HCW11-006, which was formed by WY Biotech Co., Ltd. (“WY Biotech”), a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, and the Company. Trimmune investors include CITIC Medical Fund, a multi-billion-dollar investment fund focused on innovative companies primarily targeting pharmaceuticals, biotechnology, medical devices, and diagnostics, and TigerYeah Capital Fund of TigerMed, a global leading Contract Research Organization. Trimmune is led by a team with an impressive track record for success in the development and commercialization of innovative drugs that treat diseases with large, unmet medical needs for the Chinese market.
The upfront license fee included a cash fee of
About HCW Biologics:
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and possibly extend longevity. Chronic inflammation is believed to be a significant contributing factor to the cause of conditions that diminish healthspan, including many types of cancer, autoimmune diseases and other proinflammatory diseases such as neurodegenerative diseases, as well as senescence-associated dysplasia, such as bronchopulmonary dysplasia, that impact quality-of-life but are not life-threatening. HCW9206, the Company’s commercial asset, is a commercialization-ready compound that supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer. The Company’s lead product candidate for its autoimmune program is HCW9302, which is subcutaneously injectable, first-in-kind interleukin-2 (“IL-2”) fusion molecule constructed using the Company’s TOBI™ platform technology. HCW9302 is currently being evaluated in a Phase 1 clinical study in patients with alopecia areata, which initiated in November 2025 (NCT07049328). The Company has identified two preclinical lead product candidates which are currently in IND-enabling stage for internal development constructed with its proprietary TRBC drug discovery and development platform. HCW11-018b (“Big BiTE”) is a tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (“BiTE”) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors. HCW11-040 is a pembrolizumab-based, tetra-valent immune checkpoint inhibitor. To improve efficacy, HCW11-040 is equipped with other moieties in addition to pembrolizumab which neutralizes the immunosuppressive cytokine, TGF-β, and activates effector immune cell responses. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the success of Phase 1 clinical trials to evaluate HCW11-006 and the Company’s commitment to exercise its options for rights to Americas, Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
Chief Financing Officer
HCW Biologics Inc.
RebeccaByam@HCWBiologics.com
